case_images: PMC5240268_01
case_images: Response to PD-1 inhibition in patient with renal medullary carcinoma. a CT chest with contrast showing mediastinal lymphadenopathy prior to treatment with nivolumab (b) CT chest with contrast showing resolution of mediastinal lymphadenopathy after nine months on treatment with nivolumab
case_images: 40425_2016_206_Fig1_HTML.jpg
case_images: PMC5240268_01_40425_2016_206_Fig1_HTML.jpg
case_images: Fig1
case_images: At completion of his radiotherapy, PET imaging showed resolution of the para-aortic lymph node targeted by radiation, but multiple new enlarged sub-carinal and mediastinal lymph nodes (Fig. 1a).  Now nine months after initiation of PD-1 inhibition, his CT scan showed complete response (Fig. 1b) almost 32 months from the time of his initial diagnosis.
case_images: Immunologic correlates by automated quantitative analysis. a 20x, DAPI in blue, cytokeratin in green, PD-1 in yellow, and PD-L1 in red. b 20x, DAPI blue, cytokeratin yellow, CD8 green, and CD4 red
case_images: 40425_2016_206_Fig2_HTML.jpg
case_images: PMC5240268_01_40425_2016_206_Fig2_HTML.jpg
case_images: Fig2
case_images: This assay demonstrated substantial expression of PD-L1 (E1L3N antibody) by 23% of tumor cells, and modest expression of both PD-1 and PD-L1 by stromal components (2% and 5% of cells respectively; Fig. 2).